{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:10:15Z","timestamp":1739635815927,"version":"3.37.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,15]]},"DOI":"10.7759\/cureus.79052","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T15:42:21Z","timestamp":1739634141000},"source":"Crossref","is-referenced-by-count":0,"title":["Direct Oral Anticoagulants Versus Vitamin K Antagonists in Chronic Kidney Disease Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ricardo","family":"Rodriguez Mejia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol","family":"Bahekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thirumala Keerthi Chandrika","family":"Kammaripalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000923","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto CM","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, et al.. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021, 143:e72-e227. 10.1161\/CIR.0000000000000923","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients","volume":"380","author":"Mack MJ","year":"2019","unstructured":"Mack MJ, Leon MB, Thourani VH, et al.. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019, 380:1695-705. 10.1056\/NEJMoa1814052","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV10I9A183","article-title":"Impact of chronic kidney disease on the outcomes of transcatheter aortic valve implantation: results from the FRANCE 2 registry","volume":"10","author":"Oguri A","year":"2015","unstructured":"Oguri A, Yamamoto M, Mouillet G, et al.. Impact of chronic kidney disease on the outcomes of transcatheter aortic valve implantation: results from the FRANCE 2 registry. EuroIntervention. 2015, 10:e1-9. 10.4244\/EIJV10I9A183","journal-title":"EuroIntervention"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.05.020","article-title":"Dialysis following transcatheter aortic\u00a0valve replacement: risk\u00a0factors\u00a0and\u00a0outcomes: an analysis from the UK TAVI (transcatheter\u00a0aortic valve\u00a0implantation) registry","volume":"10","author":"Ferro CJ","year":"2017","unstructured":"Ferro CJ, Law JP, Doshi SN, et al.. Dialysis following transcatheter aortic\u00a0valve replacement: risk\u00a0factors\u00a0and\u00a0outcomes: an analysis from the UK TAVI (transcatheter\u00a0aortic valve\u00a0implantation) registry. JACC Cardiovasc Interv. 2017, 10:2040-7. 10.1016\/j.jcin.2017.05.020","journal-title":"JACC Cardiovasc Interv"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.08.020","article-title":"Predictors of 1-year mortality after transcatheter aortic valve implantation in patients with and without advanced chronic kidney disease","volume":"120","author":"Levi A","year":"2017","unstructured":"Levi A, Codner P, Masalha A, et al.. Predictors of 1-year mortality after transcatheter aortic valve implantation in patients with and without advanced chronic kidney disease. Am J Cardiol. 2017, 120:2025-30. 10.1016\/j.amjcard.2017.08.020","journal-title":"Am J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2017.08.002","article-title":"Effect of diabetes mellitus on clinical outcomes and quality of life after transcatheter aortic valve implantation for severe aortic valve stenosis","volume":"59","author":"Tokarek T","year":"2018","unstructured":"Tokarek T, Dziewierz A, Wiktorowicz A, et al.. Effect of diabetes mellitus on clinical outcomes and quality of life after transcatheter aortic valve implantation for severe aortic valve stenosis. Hellenic J Cardiol. 2018, 59:100-7. 10.1016\/j.hjc.2017.08.002","journal-title":"Hellenic J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S105771","article-title":"Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations","volume":"10","author":"Lutz J","year":"2017","unstructured":"Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2017, 10:135-43. 10.2147\/IJNRD.S105771","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002220","article-title":"New insights into the role of chronic kidney disease in patients undergoing transcatheter aortic valve implantation","volume":"13","author":"Gargiulo G","year":"2020","unstructured":"Gargiulo G, Capodanno D, Sannino A, et al.. New insights into the role of chronic kidney disease in patients undergoing transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2020, 13:75-89. 10.1161\/CIRCINTERVENTIONS.114.002220","journal-title":"JACC Cardiovasc Interv"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2020.09.013","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR","volume":"13","author":"Kawashima H","year":"2020","unstructured":"Kawashima H, Watanabe Y, Hioki H, et al.. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR. JACC Cardiovasc Interv. 2020, 13:2587-97. 10.1016\/j.jcin.2020.09.013","journal-title":"JACC Cardiovasc Interv"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides SV","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, et al.. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020, 41:543-603. 10.1093\/eurheartj\/ehz405","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K anticoagulant agents in\u00a0patients with advanced chronic kidney\u00a0disease or on dialysis with AF","volume":"67","author":"Chan KE","year":"2016","unstructured":"Chan KE, Giugliano RP, Patel MR, et al.. Nonvitamin K anticoagulant agents in\u00a0patients with advanced chronic kidney\u00a0disease or on dialysis with AF. J Am Coll Cardiol. 2016, 67:2888-99. 10.1016\/j.jacc.2016.02.082","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel J","year":"2021","unstructured":"Steffel J, Collins R, Antz M, et al.. 2021 European Heart Rhythm Association Practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021, 23:1612-76. 10.1093\/europace\/euab065","journal-title":"Europace"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al.. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021, 42:373-498. 10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.11.004","article-title":"Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study","volume":"65","author":"Limdi NA","year":"2015","unstructured":"Limdi NA, Nolin TD, Booth SL, et al.. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis. 2015, 65:701-9. 10.1053\/j.ajkd.2014.11.004","journal-title":"Am J Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan KE","year":"2015","unstructured":"Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015, 131:972-9. 10.1161\/CIRCULATIONAHA.114.014113","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000535546","article-title":"Anticoagulation in Patients with Chronic Kidney Disease","volume":"55","author":"Elenjickal EJ","year":"2024","unstructured":"Elenjickal EJ, Travlos CK, Marques P, Mavrakanas TA. Anticoagulation in Patients with Chronic Kidney Disease. Am J Nephrol. 2024, 55:146-64. 10.1159\/000535546","journal-title":"Am J Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309266","article-title":"Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease","volume":"103","author":"Yang F","year":"2017","unstructured":"Yang F, Hellyer JA, Than C, et al.. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart. 2017, 103:818-26. 10.1136\/heartjnl-2016-309266","journal-title":"Heart"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.04.013","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis","volume":"132","author":"Coleman CI","year":"2019","unstructured":"Coleman CI, Kreutz R, Sood NA, Bunz TJ, Eriksson D, Meinecke AK, Baker WL. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. Am J Med. 2019, 132:1078-83. 10.1016\/j.amjmed.2019.04.013","journal-title":"Am J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy054","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary","volume":"20","author":"Steffel J","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, et al.. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018, 20:1231-42. 10.1093\/europace\/euy054","journal-title":"Europace"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons","volume":"140","author":"January CT","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al.. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019, 140:e125-51. 10.1161\/CIR.0000000000000665","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2018.19","article-title":"Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction","volume":"14","author":"Potpara TS","year":"2018","unstructured":"Potpara TS, Ferro CJ, Lip GY. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol. 2018, 14:337-51. 10.1038\/nrneph.2018.19","journal-title":"Nat Rev Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010083","article-title":"Thromboembolic and bleeding risk in atrial fibrillation patients with chronic kidney disease: role of anticoagulation therapy","volume":"10","author":"Magnocavallo M","year":"2020","unstructured":"Magnocavallo M, Bellasi A, Mariani MV, et al.. Thromboembolic and bleeding risk in atrial fibrillation patients with chronic kidney disease: role of anticoagulation therapy. J Clin Med. 2020, 10:83. 10.3390\/jcm10010083","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021890","article-title":"On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF","volume":"134","author":"Fordyce CB","year":"2016","unstructured":"Fordyce CB, Hellkamp AS, Lokhnygina Y, et al.. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation. 2016, 134:37-47. 10.1161\/CIRCULATIONAHA.116.021890","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.12.029","article-title":"Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure: systematic review and meta-analysis of randomized trials","volume":"149","author":"Raccah BH","year":"2016","unstructured":"Raccah BH, Perlman A, Danenberg HD, Pollak A, Muszkat M, Matok I. Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure: systematic review and meta-analysis of randomized trials. Chest. 2016, 149:1516-24. 10.1016\/j.chest.2015.12.029","journal-title":"Chest"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011373.pub2","article-title":"Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease","volume":"11","author":"Kimachi M","year":"2017","unstructured":"Kimachi M, Furukawa TA, Kimachi K, et al.. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017, 11:CD011373. 10.1002\/14651858.CD011373.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cells11203214","article-title":"Anticoagulants: a short history, their mechanism of action, pharmacology, and indications","volume":"11","author":"Heestermans M","year":"2022","unstructured":"Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Anticoagulants: a short history, their mechanism of action, pharmacology, and indications. Cells. 2022, 11:3214. 10.3390\/cells11203214","journal-title":"Cells"},{"key":"ref27","unstructured":"U.S. Food and Drug. FDA drug safety communication: updated recommendations to decrease risk of spinal column bleeding and paralysis in patients on direct oral anticoagulants. (2016). Accessed: December 23, 2024: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-updated-recommendations-decrease...."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris PA","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009, 42:377-81. 10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris PA","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al.. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019, 95:103208. 10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fbinf.2024.1305969","article-title":"MetaWin 3: open-source software for meta-analysis","volume":"4","author":"Rosenberg MS","year":"2024","unstructured":"Rosenberg MS. MetaWin 3: open-source software for meta-analysis. Front Bioinform. 2024, 4:1305969. 10.3389\/fbinf.2024.1305969","journal-title":"Front Bioinform"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.08.067","article-title":"Predictors of all-cause mortality after successful transcatheter aortic valve implantation in patients with atrial fibrillation","volume":"207","author":"Yamamoto M","year":"2023","unstructured":"Yamamoto M, Hayashida K, Hengstenberg C, et al.. Predictors of all-cause mortality after successful transcatheter aortic valve implantation in patients with atrial fibrillation. Am J Cardiol. 2023, 207:150-8. 10.1016\/j.amjcard.2023.08.067","journal-title":"Am J Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2023-322548","article-title":"Direct oral anticoagulants versus vitamin K antagonist after transcatheter aortic valve implantation","volume":"109","author":"Hohmann C","year":"2023","unstructured":"Hohmann C, Pfister R, Frerker C, et al.. Direct oral anticoagulants versus vitamin K antagonist after transcatheter aortic valve implantation. Heart. 2023, 109:1706-13. 10.1136\/heartjnl-2023-322548","journal-title":"Heart"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-018-1247-x","article-title":"NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation","volume":"107","author":"Geis NA","year":"2018","unstructured":"Geis NA, Kiriakou C, Chorianopoulos E, Uhlmann L, Katus HA, Bekeredjian R. NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol. 2018, 107:799-806. 10.1007\/s00392-018-1247-x","journal-title":"Clin Res Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz064","article-title":"Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation","volume":"7","author":"Butt JH","year":"2021","unstructured":"Butt JH, De Backer O, Olesen JB, et al.. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2021, 7:11-9. 10.1093\/ehjcvp\/pvz064","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2021.05.025","article-title":"TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist?","volume":"14","author":"Didier R","year":"2021","unstructured":"Didier R, Lhermusier T, Auffret V, et al.. TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist?. JACC Cardiovasc Interv. 2021, 14:1704-13. 10.1016\/j.jcin.2021.05.025","journal-title":"JACC Cardiovasc Interv"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes\u00a0after transcatheter aortic\u00a0valve replacement","volume":"12","author":"Jochheim D","year":"2019","unstructured":"Jochheim D, Barbanti M, Capretti G, et al.. Oral anticoagulant type and outcomes\u00a0after transcatheter aortic\u00a0valve replacement. JACC Cardiovasc Interv. 2019, 12:1566-76. 10.1016\/j.jcin.2019.03.003","journal-title":"JACC Cardiovasc Interv"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.10.023","article-title":"Apixaban in patients with atrial\u00a0fibrillation\u00a0after transfemoral aortic\u00a0valve\u00a0replacement","volume":"10","author":"Seeger J","year":"2017","unstructured":"Seeger J, Gonska B, Rodewald C, et al.. Apixaban in patients with atrial\u00a0fibrillation\u00a0after transfemoral aortic\u00a0valve\u00a0replacement. JACC Cardiovasc Interv. 2017, 10:66-74. 10.1016\/j.jcin.2016.10.023","journal-title":"JACC Cardiovasc Interv"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023561","article-title":"Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: insights from the STS\/ACC TVT registry","volume":"11","author":"Tanawuttiwat T","year":"2022","unstructured":"Tanawuttiwat T, Stebbins A, Marquis-Gravel G, Vemulapalli S, Kosinski AS, Cheng A. Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: insights from the STS\/ACC TVT registry. J Am Heart Assoc. 2022, 11:e023561. 10.1161\/JAHA.121.023561","journal-title":"J Am Heart Assoc"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet JP","year":"2022","unstructured":"Collet JP, Van Belle E, Thiele H, et al.. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022, 43:2783-97. 10.1093\/eurheartj\/ehac242","journal-title":"Eur Heart J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem NM","year":"2021","unstructured":"Van Mieghem NM, Unverdorben M, Hengstenberg C, et al.. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021, 385:2150-60. 10.1056\/NEJMoa2111016","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00939-x","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements","volume":"40","author":"Pasciolla S","year":"2020","unstructured":"Pasciolla S, Zizza LF, Le T, Wright K. Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements. Clin Drug Investig. 2020, 40:839-45. 10.1007\/s40261-020-00939-x","journal-title":"Clin Drug Investig"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026666","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair","volume":"11","author":"Mentias A","year":"2022","unstructured":"Mentias A, Saad M, Michael M, et al.. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair. J Am Heart Assoc. 2022, 11:e026666. 10.1161\/JAHA.122.026666","journal-title":"J Am Heart Assoc"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen A","year":"2020","unstructured":"Chen A, Stecker E, A Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020, 9:e017559. 10.1161\/JAHA.120.017559","journal-title":"J Am Heart Assoc"},{"key":"ref44","unstructured":"FDA Drug Safety Communication. Updated recommendations to decrease risk of spinal column bleeding and paralysis in patients on low molecular weight heparins. (2016). Accessed: Dec 23, 2024: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-updated-recommendations-decrease...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/338807-direct-oral-anticoagulants-versus-vitamin-k-antagonists-in-chronic-kidney-disease-patients-undergoing-transcatheter-aortic-valve-replacement-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T15:42:24Z","timestamp":1739634144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/338807-direct-oral-anticoagulants-versus-vitamin-k-antagonists-in-chronic-kidney-disease-patients-undergoing-transcatheter-aortic-valve-replacement-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.79052","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,15]]}}}